Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
EmailIphone Application    Posted: 21st September 2022
If you would like to forward this story on to a friend, simply fill in the form below and click send.
Your friend's email:
Your email:
Your name:
 
 
Send Cancel

First bovine respiratory disease vaccine for newborn calves
BOVILIS® INtranasal RSP™ Live vaccine is now licensed for use in calves from birth onwards.

MSD announces only BRD vaccine that can be administered in early life. 

MSD Animal Health has announced the first bovine respiratory disease (BRD) vaccine for newborn calves.

In a press release, the manufacturer said its new BOVILIS® INtranasal RSP™ Live vaccine is now licensed for use in calves from birth onwards. 

It is the only BRD vaccine that can be administered in early life – a significant advantage given that the sooner young calves can be protected from viral BRD and the harm it causes, the better.

An MSD Animal Health spokesperson said: “BOVILISâ INtranasal RSPä Live delivers the fastest on-farm protection of all the available pneumonia vaccines, with an onset of immunity after administration for BRSV of just six days (for calves vaccinated from the day of birth onwards) and five days (for calves vaccinated from the age of one week onwards). 

“Onset of immunity after administration for Pi3V is one week after vaccination. The duration of immunity is 12 weeks for both viruses.”

BRD is caused by bovine respiratory syncytial virus (BRSV) and parainfluenza virus 3 (Pi3).

Early and fast protection against pneumonia is important. Indeed, research published in the Journal of Dairy Science shows that replacement heifers that do not suffer pneumonia while they are calves produce more than 500 kg more milk during their first lactation. 

“BOVILIS® INtranasal RSP™ Live also has significant practical usage benefits in that it can now be used on farm at the same time as other early life interventions associated with newborn calves – for example, colostrum/first milk feeding, navel management, tagging, jacketing and necessary pen movements,” the spokesperson continued.

“Additionally, BOVILIS® INtranasal RSP™ Live can be used up to six hours after mixing with the solvent, which is the longest of all the available intranasal vaccines for these pathogens. It is supplied as a farm-friendly, easy-to administer nasal suspension product that doesn’t need a specific applicator – although for maximum flexibility an easy-clean injector and nozzle kit is available for vaccinating multiple animals.”

Become a member or log in to add this story to your CPD history

Defra shares new Sanitary and Phytosanitary guidance

News Story 1
 Defra has published guidance for the vet sector ahead of a proposed UK-EU Sanitary and Phytosanitary agreement.

The agreement, which will change the movement and trade of animals and related products, could see reductions in checks, paperwork and certification. As well as describing regulatory developments, the advice highlights the importance of animal ID, registration and traceability in disease control and other compliance arrangements.

The guidance can be found here. More detail is expected as negotiations progress. 

Click here for more...
News Shorts
Lords Committee opens Pet Parasite Medication inquiry

The House of Lords Environment and Climate Change Committee will launch its inquiry into Pet Parasite Medication (PPM) on Wednesday (3 June).

Focusing on treatments containing fipronil and imidacloprid, the inquiry will seek to understand distribution pathways and the impacts of PPM use and non-use on biodiversity and human health. It will also cover current regulation, monitoring, and the potential implications for pets and their owners.

The committee will hear evidence from environmental non-governmental organisations and research institutes. The public can follow the proceedings live on Parliament TV or in person in the Palace of Westminster.